S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
TXMD · TherapeuticsMD, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
TherapeuticsMD Inc (TXMD)
NASDAQ NMS - GLOBAL MARKET
Pharmaceuticals
$1.90
+0.02
(+1.06%)
● At close: October 20 at 4:00:00 PM EDT
DAY'S RANGE
$1.90
$1.84
$1.90
52-WEEK RANGE
$1.90
$1.08
$2.95
What's happening
- TXMD is up 1.06% today, trading at $1.90. — Live quote
- Volume today (679) is well below its 3-month average of 30,310. (Finnhub fundamentals)
- Reports earnings on 2026-11-10, 19 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-0.13 actual vs. $-0.05 estimated (-154.9%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 0
Buy 0
Hold 3
Sell 1
Strong sell 2
Aggregate ratings for 2024-02-01 (6 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
TXMD
+15.34%
vs S&P 500
+2.56%
1-YEAR RETURN
TXMD
+63.48%
vs S&P 500
+48.92%
6-MONTH RETURN
TXMD
-9.62%
3-MONTH RETURN
TXMD
-7.84%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2023-10-26 (Q3 2023)
$-0.13
Est. $-0.05
MISS -154.9%
2023-07-26 (Q2 2023)
$-0.24
Est. $-0.07
MISS -236.1%
2023-04-26 (Q1 2023)
$-0.37
Est. $0.06
MISS -704.6%
2023-01-26 (Q4 2022)
$8.23
Est. $-1.13
BEAT +826.9%
Valuation Measures & Ratios
Enterprise Value4$12.5M
Forward P/E511.24
PEG Ratio6—
Price / Sales (TTM1)6.64
Price / Book70.94
EV4 / Revenue3.83
EV4 / EBITDA0.21
Profit Margin-6.64%
Operating Margin-120.89%
Return on Equity (ROE8)-0.80%
Return on Assets (ROA9)-0.57%
Avg Volume (3M)30,310
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $32.4M | $21.8M | $16.3M | $13.2M | $10.9M |
| P/E | 33.99 | 150.03 | -29.23 | -7.34 | -3.53 |
| Price/Book | 1.19 | 0.81 | 0.60 | 0.48 | 0.41 |
| ROE | 3.51% | 0.54% | -2.04% | -6.60% | -11.54% |
| ROA | 2.54% | 0.39% | -1.45% | -4.68% | -8.07% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short23,663
Change from Prior Settlement-10.49%
% of Float—
Days to Cover (Short Ratio)1.39
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Trailing 52-week price return is +63.5%. Finnhub market metrics ↗
- Latest SEC filing is Form 10-Q, filed 2026-08-11; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Revenue growth is -8.7% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is -6.6%. Finnhub fundamentals ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on TXMD
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $724.0K | — | — | $393.0K | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$816.0K | -$723.0K | -$862.0K | -$695.0K | -$1.3M | -$1.1M | -$2.8M | -$1.1M |
| Net income | $155.0K | $95.0K | $152.0K | $551.0K | -$653.0K | -$609.0K | -$1.1M | -$734.0K |
| EPS (diluted) | $0.01 | $0.01 | $0.01 | $0.05 | $-0.06 | $-0.05 | $-0.09 | $-0.06 |
| EPS (basic) | $0.01 | $0.01 | $0.01 | $0.05 | $-0.06 | $-0.05 | $-0.09 | $-0.06 |
| Operating margin | — | -$100 | — | — | -$326 | — | — | — |
| Net margin | — | $13 | — | — | -$166 | — | — | — |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $37.5M | $37.6M | $37.7M | $38.7M | $38.5M | $38.2M | $38.8M | — |
| Total liabilities | $10.4M | $10.6M | $10.8M | $11.2M | $11.2M | $11.5M | $11.5M | — |
| Stockholders' equity | $27.1M | $27.0M | $26.9M | $27.4M | $27.3M | $26.7M | $27.4M | $27.1M |
| Total current assets | $16.1M | $15.3M | $14.4M | $14.5M | $13.5M | $12.5M | $12.3M | — |
| Total current liabilities | $5.0M | $4.9M | $4.8M | $4.9M | $4.7M | $4.7M | $5.2M | — |
| Cash & equivalents | — | — | — | — | — | $5.7M | $5.1M | — |
| Accounts receivable | — | — | — | — | — | — | — | — |
| Inventory | — | — | — | — | — | — | — | — |
| Other current assets | — | — | — | — | — | — | — | — |
| Property, plant & equipment | — | — | — | — | — | — | — | — |
| Goodwill | — | — | — | — | — | — | — | — |
| Intangible assets | $3.6M | $3.7M | $3.8M | $3.9M | $4.0M | $4.1M | $4.3M | — |
| Other non-current assets | $395.0K | $419.0K | $444.0K | $470.0K | $428.0K | $211.0K | $130.0K | — |
| Accounts payable | $460.0K | $15.0K | $377.0K | $263.0K | $350.0K | $176.0K | $258.0K | — |
| Short-term debt | — | — | — | — | — | — | — | — |
| Other current liabilities | — | — | — | — | — | — | — | — |
| Long-term debt | — | — | — | — | — | — | — | — |
| Other non-current liabilities | $873.0K | $873.0K | $873.0K | $871.0K | $832.0K | $795.0K | $744.0K | — |
| Common stock & paid-in capital | $11.0K | $11.0K | $11.0K | $11.0K | $11.0K | $11.0K | $11.0K | — |
| Retained earnings | -$952.1M | -$952.3M | -$952.4M | -$951.8M | -$951.9M | -$952.5M | -$951.8M | — |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | — | — | — | — | — | — | — | — |
| Investing cash flow | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — |
| Capital expenditures | — | — | — | — | — | — | — | — |
| Depreciation & amortization | $95.0K | $94.0K | — | — | $96.0K | $95.0K | — | — |
| Share-based compensation | $4.0K | $2.0K | $51.0K | $0 | $1.0K | $23.0K | $24.0K | $33.0K |
| Change in accounts receivable | — | — | — | — | — | — | — | — |
| Change in inventory | — | — | — | — | — | — | — | — |
| Change in accounts payable | $423.0K | -$340.0K | $114.0K | -$87.0K | $174.0K | -$82.0K | $24.0K | $91.0K |
| Purchases of investments | — | — | — | — | — | — | — | — |
| Debt issued | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | — | $1.8M | $1.3M | $70.0M | — |
| Gross profit | — | — | $1.3M | $68.6M | $1.2M |
| Operating income | -$4.4M | -$6.1M | -$8.5M | $1.2M | -$79.6M |
| Net income | -$569.0K | -$2.2M | -$10.3M | $112.0M | -$172.4M |
| EPS (diluted) | $-0.05 | $-0.19 | $-0.99 | $11.96 | $-21.66 |
| EPS (basic) | $-0.05 | $-0.19 | $-0.99 | $12.41 | $-21.66 |
| Operating margin | — | -$347 | -$655 | $2 | — |
| Net margin | — | -$124 | -$789 | $160 | — |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $37.7M | $38.8M | $43.3M | $90.5M | $169.5M |
| Total liabilities | $10.8M | $11.5M | $14.0M | $55.3M | $263.1M |
| Stockholders' equity | $26.9M | $27.4M | $29.3M | $35.1M | -$93.6M |
| Total current assets | $14.4M | $12.3M | $11.8M | $55.4M | $119.5M |
| Total current liabilities | $4.8M | $5.2M | $6.9M | $46.8M | $252.9M |
| Cash & equivalents | — | $5.1M | $4.3M | — | — |
| Accounts receivable | — | — | — | — | $36.2M |
| Inventory | — | — | — | — | $7.6M |
| Other current assets | — | — | — | — | — |
| Property, plant & equipment | — | — | — | $78.0K | $823.0K |
| Intangible assets | $3.8M | $4.3M | $6.1M | $6.9M | $7.1M |
| Other non-current assets | $444.0K | $130.0K | $58.0K | $253.0K | $253.0K |
| Accounts payable | $377.0K | $258.0K | $27.0K | $2.2M | $3.4M |
| Short-term debt | — | — | — | — | $188.3M |
| Other current liabilities | — | — | — | $18.8M | $13.3M |
| Long-term debt | — | — | — | — | $188.3M |
| Other non-current liabilities | $873.0K | $744.0K | $636.0K | $1.1M | $2.1M |
| Common stock & paid-in capital | $11.0K | $11.0K | $11.0K | $9.0K | $9.0K |
| Retained earnings | -$952.4M | -$951.8M | -$949.6M | -$939.4M | -$1.05B |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | — | — | — | — | -$142.7M |
| Investing cash flow | — | — | — | — | -$2.2M |
| Financing cash flow | — | — | $3.2M | — | $129.6M |
| Free cash flow | — | — | — | — | -$142.7M |
| Capital expenditures | — | — | — | — | $34.0K |
| Depreciation & amortization | — | — | — | — | — |
| Share-based compensation | $75.0K | $264.0K | $1.3M | $11.6M | $18.1M |
| Change in accounts receivable | — | — | — | — | $4.3M |
| Change in inventory | — | — | — | — | $711.0K |
| Change in accounts payable | $119.0K | $231.0K | -$2.1M | -$1.2M | -$1.1M |
| Debt issued | — | — | — | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding TXMD as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2023-04-12 to 2025-12-23
Recent transactions
- Most recent: Thompson Tommy G (Reporting person) — Open market purchase of 8,400 shares on 2025-12-23.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)0 sh(0 txns)
Net Shares+0
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Thompson Tommy G | Reporting person | Open market purchase | 2025-12-23 | 8,400 |
| Walker Marlan D | Chief Executive Officer | Open market purchase | 2025-04-14 | 490 |
| Collins Cooper C. | Reporting person | Option exercise | 2025-02-18 | 8,500 |
| Naughton Gail K | Reporting person | Option exercise | 2025-02-18 | 8,500 |
| Rubric Capital Management LP | Director | Grant / award | 2023-11-15 | 877,192 |
| ZIEGLER JOSEPH | Principal Financial Officer | Grant / award | 2023-08-17 | 7,500 |
| Donegan Michael C | Prin. Fin. and Acctg. Officer | Option exercise | 2023-04-12 | 50,000 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2025-12-23 | Thompson Tommy G | Reporting person | Open market purchase | 8,400 | $1.67 |
| 2025-04-14 | Thompson Tommy G | Reporting person | Open market purchase | 325 | $1.00 |
| 2025-04-14 | Walker Marlan D | Chief Executive Officer | Open market purchase | 490 | $1.00 |
| 2025-04-10 | Walker Marlan D | Chief Executive Officer | Open market purchase | 1,167 | $0.86 |
| 2025-04-09 | Walker Marlan D | Chief Executive Officer | Open market purchase | 1,136 | $0.87 |
| 2025-02-18 | Collins Cooper C. | Reporting person | Option exercise | 8,500 | $0.00 |
| 2025-02-18 | Naughton Gail K | Reporting person | Option exercise | 8,500 | $0.00 |
| 2025-02-18 | Thompson Tommy G | Reporting person | Option exercise | 8,500 | $0.00 |
| 2025-02-18 | Walker Marlan D | Chief Executive Officer | Option exercise | 3,467 | $0.00 |
| 2025-02-18 | Walker Marlan D | Chief Executive Officer | Option exercise | 2,311 | $0.00 |
| 2025-02-18 | Walker Marlan D | Chief Executive Officer | Option exercise | 770 | $0.00 |
| 2025-02-18 | Walker Marlan D | Chief Executive Officer | Option exercise | 1,733 | $0.00 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-21 23:28 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-08-11 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-11 | 8-K | 2026-08-11 | View on SEC.gov → |
| 2026-05-12 | 10-Q | 2026-03-31 | View on SEC.gov → |
| 2026-05-12 | 8-K | 2026-05-02 | View on SEC.gov → |
| 2026-03-30 | 8-K | 2026-03-30 | View on SEC.gov → |
| 2026-03-30 | 10-K | 2025-12-31 | View on SEC.gov → |
| 2026-01-21 | 8-K | 2026-01-15 | View on SEC.gov → |
| 2025-12-29 | 4 | 2025-12-23 | View on SEC.gov → |
| 2025-12-16 | 8-K | 2025-12-15 | View on SEC.gov → |
| 2025-11-13 | 8-K | 2025-11-12 | View on SEC.gov → |
| 2025-11-12 | 10-Q | 2025-09-30 | View on SEC.gov → |
| 2025-11-05 | 4 | 2025-11-03 | View on SEC.gov → |
Recent news
Headlines about TXMD (TherapeuticsMD, Inc.). Links open the publisher — we don’t host full articles.
-
TherapeuticsMD Inc. stock outperforms competitors on strong trading day
MarketWatch · 2026-10-21 -
TherapeuticsMD Inc. stock underperforms Tuesday when compared to competitors despite daily gains
MarketWatch · 2026-10-20 -
TherapeuticsMD Inc. stock underperforms Monday when compared to competitors
MarketWatch · 2026-10-19 -
TherapeuticsMD Inc. stock underperforms Friday when compared to competitors
MarketWatch · 2026-10-16 -
TherapeuticsMD Inc. stock underperforms Thursday when compared to competitors
MarketWatch · 2026-10-15 -
Therapeutics MD reports Q2 results
Seeking Alpha · 2026-08-11 -
TherapeuticsMD Announces Second Quarter 2026 Financial Results
Yahoo Finance · 2026-08-11
No headlines in this category right now — try “All”.